Long-term feeding outcomes after infant tracheostomy.

Objective: To characterize long-term feeding outcomes in infants who underwent tracheostomy prior to their first birthday.

Study Design: Retrospective review of feeding outcomes at initial hospital discharge and age 5 in a cohort of infants who underwent tracheostomy at a children's hospital over a 16-year period.

Results: 145 infants met inclusion criteria.

Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.

Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) is a triple combination drug therapy approved for individuals with cystic fibrosis (CF) who possess at least one copy of the F508del cystic fibrosis transmembrane conductance regulator (CFTR) variant. ELX/TEZ/IVA improves lung function and decreases the frequency of CF exacerbations in clinical studies, which has led to investigation of this therapy on rare CFTR variants. Rare mutations have limited research publications; therefore, reporting outcomes is critical to expanding knowledge and understanding of therapeutic efficacy.